Report of the Second European Expert Meeting on Rotavirus Vaccination

Vaccine

Volumn 30, Issue 13, 2012, Pages 2237-2244

  Giaquinto, Carlo ^a   Jackson, Amy E M ^b   Vesikari, Timo ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b Fishawack Communications   (United Kingdom)

^c UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

Author keywords

Meeting; Rotarix ; RotaTeq ; Rotavirus; UMV; Vaccine

Indexed keywords

ROTAVIRUS VACCINE;

CIRCOVIRUS; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; INTUSSUSCEPTION; ISRAEL; NONHUMAN; PRIORITY JOURNAL; ROTAVIRUS; ROTAVIRUS INFECTION; SOUTH AND CENTRAL AMERICA; UNITED STATES; VACCINATION;

AMERICAS; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; EUROPE; HUMANS; IMMUNITY, HERD; ISRAEL; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TREATMENT OUTCOME; VACCINATION;

EID: 84857782406     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.002     Document Type: Conference Paper

References (56)

1. Vesikari T., Van Damme P., Giaquinto C., Gray J., Mrukowicz J., Dagan R., et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008, 46:615-618.
2. WHO Wkly Epidemiol Rec 2009, 84:213-236.
3. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375:1969-1987.
4. Parashar U.D., Burton A., Lanata C., Boschi-Pinto C., Shibuya K., Steele D., et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009, 200(Suppl. 1):S9-S15.
5. Atherly D., Dreibelbis R., Parashar U.D., Levin C., Wecker J., Rheingans R.D. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009, 200(Suppl. 1):S28-S38.
6. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
7. Vesikari T., Karvonen A., Ferrante S.A., Kuter B.J., Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010, 29:957-963.
8. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
9. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
10. Boom J.A., Tate J.E., Sahni L.C., Rench M.A., Hull J.J., Gentsch J.R., et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010, 125:e199-e207.
11. Wang F.T., Mast T.C., Glass R.J., Loughlin J., Seeger J.D. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010, 125:e208-e213.
12. Lambert S.B., Faux C.E., Hall L., Birrell F.A., Peterson K.V., Selvey C.E., et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust 2009, 191:157-160.
13. Gagneur A., Nowak E., Lemaitre T., Segura J.F., Delaperriere N., Abalea L., et al. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study. Vaccine 2011, 29:3753-3759.
14. Clark H.F., Marcello A.E., Lawley D., Reilly M., DiNubile M.J. Unexpectedly high burden of rotavirus gastroenteritis in very young infants. BMC Pediatr 2010, 10:40.
15. Forster J., Guarino A., Parez N., Moraga F., Roman E., Mory O., et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009, 123:e393-e400.
16. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
17. Linhares A.C., Velazquez F.R., Perez-Schael I., Saez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371:1181-1189.
18. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A., Huang L.M., Quak S.H., et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009, 27:5936-5941.
19. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
20. Neuzil K., Madhi S., Cunliffe N., Kirsten M., Bos P., Witte D., et al. RIX4414 is protective against severe RVGE caused by diverse rotavirus serotypes during the first year of life in African infants. 27th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID) 2009.
21. do Carmo G.M., Yen C., Cortes J., Siqueira A.A., de Oliveira W.K., Cortez-Escalante J.J., et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med 2011, 8:e1001024.
22. Richardson V., Hernandez-Pichardo J., Quintanar-Solares M., Esparza-Aguilar M., Johnson B., Gomez-Altamirano C.M., et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010, 362:299-305.
23. de Palma O., Cruz L., Ramos H., de Baires A., Villatoro N., Pastor D., et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 2010, 340:c2825.
24. Braeckman T., Van Herck K., Raes M., Vergison A., Sabbe M., Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011, 30:S21-S24.
25. Patel M.M., Steele D., Gentsch J.R., Wecker J., Glass R.I., Parashar U.D. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011, 30:S1-S5.
26. Curns A.T., Steiner C.A., Barrett M., Hunter K., Wilson E., Parashar U.D. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010, 201:1617-1624.
27. Paulke-Korinek M., Rendi-Wagner P., Kundi M., Kronik R., Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 2010, 29:319-323.
28. Hanquet G., Ducoffre G., Vergison A., Neels P., Sabbe M., Van Damme P., et al. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine 2011, 29:4698-4703.
29. Raes M., Strens D., Vergison A., Verghote M., Standaert B. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 2011, 30:e120-e125.
30. Velasquez A.A., Colindres R., Grajales C., Hernandez M.T., Mercadillo M.G., Torres F.J., et al. Postmarketing surveillance of intussusception following mass introduction of the human rotavirus vaccine in Mexico: an interim analysis. Acta Paediatr 2010, 99:PP106.
31. Global Advisory Committee on Vaccine Safety Meeting of the Global Advisory Committee on Vaccine Safety, December 2010. Wkly Epidemiol Rec 2010, 86:38-43.
32. Buttery J.P., Danchin M.H., Lee K.J., Carlin J.B., McIntyre P.B., Elliott E.J., et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011, 29:3061-3066.
33. Rotavirus vaccination and risk of intussusception. Available from: ; 2011 [accessed 06.11]. http://www.tga.gov.au/safety/alerts-medicine-rotavirus-110225.htm.
34. Nylund C.M., Denson L.A., Noel J.M. Bacterial enteritis as a risk factor for childhood intussusception: a retrospective cohort study. J Pediatr 2010, 156:761-765.
35. Hsu H.Y., Kao C.L., Huang L.M., Ni Y.H., Lai H.S., Lin F.Y., et al. Viral etiology of intussusception in Taiwanese childhood. Pediatr Infect Dis J 1998, 17:893-898.
36. Mrukowicz J. Appendix I: methods for the development of evidence-based recommendations. J Pediatr Gastroenterol Nutr 2008, 46(Suppl. 2):S49-S75.
37. Vesikari T., Van Damme P., Giaquinto C., Gray J., Mrukowicz J., Dagan R., et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008, 46(Suppl. 2):S38-S48.
38. Simonsen L., Viboud C., Elixhauser A., Taylor R.J., Kapikian A.Z. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005, 192(Suppl. 1):S36-S43.
39. Cortese M.M., Parashar U.D. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009, 58:1-25.
40. Tate J.E., Panozzo C.A., Payne D.C., Patel M.M., Cortese M.M., Fowlkes A.L., et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009, 124:465-471.
41. Payne D., Staat M.A., Edward K., Szilagy P.G., Weinberg G.A., Hall C.B., et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006-2009. Clin Infect Dis 2011, 53:245-253.
42. Yen C., Armero Guardado J.A., Alberto P., Rodriguez Araujo D.S., Mena C., Cuellar E., et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 2011, 30:S6-S10.
43. Martinon-Torres F., Alejandro M.B., Collazo L.R., Lastres J.M., Diaz S.P., Pillado M.T., et al. Effectiveness of rotavirus vaccination in Spain. Hum Vaccin 2011, 7:757-761.
44. Bouzon M., Diez J., Martinon-Torres F. Circovirus and impact of temporary withdrawal of rotavirus vaccines in Spain. Hum Vaccin 2011, 7:798-799.
45. Syriopoulou V., Kafetzis D., Theodoridou M., Syrogiannopoulos G.A., Mantagos S., Trimis G., et al. Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece. Acta Paediatr 2011, 100:732-739.
46. Dube E., Gilca V., Sauvageau C., Bradet R., Bettinger J.A., Boulianne N., et al. Canadian paediatricians' opinions on rotavirus vaccination. Vaccine 2011, 29:3177-3182.
47. Zeller M., Rahman M., Heylen E., De Coster S., De Vos S., Arijs I., et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010, 28:7507-7513.
48. Nakagomi T., Cuevas L.E., Gurgel R.G., Elrokhsi S.H., Belkhir Y.A., Abugalia M., et al. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. Arch Virol 2008, 153:591-593.
49. Correia J.B., Patel M.M., Nakagomi O., Montenegro F.M., Germano E.M., Correia N.B., et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010, 201:363-369.
50. Nakagomi T., Nakagomi O. A critical review on a globally licensed, live, orally administrable, monovalent human rotavirus vaccine: Rotarix™. Expert Opin Biol Ther 2009, 9:1073-1086.
51. Sato T., Nakagomi T., Naghipour M., Nakagomi O. Modeling seasonal variation in rotavirus hospitalizations for use in evaluating the effect of rotavirus vaccine. J Med Virol 2010, 82:1468-1474.
52. De Marco G., Bracale I., Buccigrossi V., Bruzzese E., Canani R.B., Polito G., et al. Rotavirus induces a biphasic enterotoxic and cytotoxic response in human-derived intestinal enterocytes, which is inhibited by human immunoglobulins. J Infect Dis 2009, 200:813-819.
53. Paulke-Korinek M., Kundi M., Rendi-Wagner P., de Martin A., Eder G., Schmidle-Loss B., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011, 29:2791-2796.
54. Braeckman T., Van Herck K., Meyer N., Pircon J.Y., Soriano-Gabarro M., Matthijnssens J., et al. Vaccine effectiveness against community-acquired severe rotavirus gastroenteritis among young children in Belgium: a hospital-based, prospective, case control study. European Society of Paediatric Infectious Diseases (ESPID) 2011.
55. Vesikari T., Uhari M., Renko M., Hämäläinen M., Räsänen S., Salminen M., et al. A hospital-based surveillance of rotavirus acute gastroenteritis in children after introduction of routine rotavirus vaccination in Finland with live attenuated pentavalent rotavirus vaccine. European Society of Paediatric Infectious Diseases (ESPID) 2011.
56. Martinon-Torres F., Bouzon A., Redondo L., Pertega S., Seoane M.T., Martinon-Sánchez J.M., et al. Acute gastroenteritis hospitalizations before and after rotavirus vaccine introduction in north-west Spain (Galicia). European Society of Paediatric Infectious Diseases (ESPID) 2011.